Quest PharmaTech Inc. (QPTFF) announced that patient enrollment has been completed in the Phase I clinical study of SL017 Topical Gel for the photodynamic therapy of actinic keratosis ("AK"), with centers in Edmonton and Montreal.
From: www.nasdaq.com
QPTFF: Completes Patient Enrollment In Phase I Trial of SL017 Topical Gel
Posted by Ruslan Abuzant at 8:26 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment